Tulane Home Tulane Home
Subscribe to NIH Grants feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 17 hours 17 min ago

Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional)

Thu, 12/29/2022 - 09:06
Funding Opportunity RFA-MH-23-115 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) focuses on understanding bidirectional relationships between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. For the purposes of this FOA, social media are defined as internet-based communication platforms and applications that enable interactions between users by sharing or consuming information. The FOA focuses on adolescents (broadly defined here as 10-20 years of age), who have increasing access to social media and greater autonomy in their use of digital platforms. No effectiveness/efficacy trials will be accepted.

Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases

Thu, 12/29/2022 - 00:11
Notice NOT-AR-23-008 from the NIH Guide for Grants and Contracts

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)

Wed, 12/28/2022 - 11:45
Funding Opportunity PAR-23-049 from the NIH Guide for Grants and Contracts. NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program.

Notice of Corrections to PAR-23-045 Biomedical Research Facilities (C06 Clinical Trial Not Allowed)

Wed, 12/28/2022 - 08:15
Notice NOT-OD-23-051 from the NIH Guide for Grants and Contracts

NIH Operates Under a Continuing Resolution

Wed, 12/28/2022 - 08:12
Notice NOT-OD-23-052 from the NIH Guide for Grants and Contracts

Limited Competition: Brain Tissue Resource Center for Alcohol Research (R28 Clinical Trial Not Allowed)

Tue, 12/27/2022 - 01:07
Funding Opportunity PAR-23-068 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health, is a limited competition FOA encouraging a resource project (R28) application from a center currently supported under an existing grant, entitled Brain Tissue Resource Center for Alcohol Research to (i) develop a bank of brain tissues (fresh-frozen and formalin-fixed) from alcoholic and control cases with confirmed clinical and pathological diagnoses, (ii) develop and promote a prospective brain donor program in Australia (Using our Brains) to enhance the brain bank, (iii) establish an associated DNA (blood) bank from the brain donor group, and (iv) invite research groups with an interest in alcohol-related brain damage to submit applications for studies using these tissues.

NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (P30 - Clinical Trial Not Allowed)

Tue, 12/27/2022 - 01:07
Funding Opportunity RFA-AR-24-002 from the NIH Guide for Grants and Contracts. NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (P30 - Clinical Trial Not Allowed)

NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed)

Tue, 12/27/2022 - 00:58
Funding Opportunity RFA-AR-24-001 from the NIH Guide for Grants and Contracts. NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed)

Notice of Correction to Eligibility Criteria for PAR-21-315 "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)"

Tue, 12/27/2022 - 00:49
Notice NOT-NS-23-056 from the NIH Guide for Grants and Contracts

Notice of Change to PAR-22-114, Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)

Tue, 12/27/2022 - 00:46
Notice NOT-CA-23-029 from the NIH Guide for Grants and Contracts

Translational Centers for Microphysiological Systems (TraCe MPS) (U2C Clinical Trials Not Allowed)

Tue, 12/27/2022 - 00:36
Funding Opportunity RFA-TR-23-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to establish Centers to support research that will accelerate the translational use of Microphysiological Systems (MPS) in drug development through regulatory acceptance and adoption for industrial use, by establishing MPS that are fit-for-purpose for industry needs and have specific defined contexts of use (CoUs) and will be developed with consideration of applicable expectations to achieve regulatory approval. For this FOA, the term drugs refers to both human pharmacological and biological products unless otherwise specified. These Centers will further the development of MPS as drug development tools (DDTs) that, once qualified, will be made publicly and commercially available to fill unmet needs in drug development.

Small Grants to Enhance the Use of the All of Us Research Programs Data (R03 Clinical Trial Not Allowed)

Fri, 12/23/2022 - 11:52
Funding Opportunity RFA-PM-23-002 from the NIH Guide for Grants and Contracts. The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R03 grant mechanism to support data analysis using standard methods, while the companion FOA (link) uses the R21 mechanism for new tool development and application.

Understanding the Supply of Professional Dementia Care Providers and Their Decisions (U54 Clinical Trial Not Allowed)

Fri, 12/23/2022 - 11:49
Funding Opportunity RFA-AG-24-024 from the NIH Guide for Grants and Contracts. This RFA supports a national survey of professional dementia care providers and link consented survey respondents (providers and institutional representative) that consent to administrative data (e.g., electronic health records, claims, payroll, other institutional and state level data). This new resource anticipates the integration from administrative sources with the provider survey to expand research on the dementia care workforce, supply of skilled labor, and provide deeper insight into how professional care providers and institutions provide care for persons living with dementia. The national survey will oversample individuals from populations underrepresented in research on Alzheimers disease and related dementias (AD/ADRD) who serve in various professional caregiving roles (e.g., physicians, other care providers such as licensed practical nurses [LPNs], social workers) and institutions serving predominately underrepresented populations. This will allow examination of how the characteristics of professional care providers and the institutions employing them lead to variation in care provided to persons living with dementia and identify modifiable organization and individual behaviors that can improve overall health care delivery and eliminate AD/ADRD disparities.

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)

Fri, 12/23/2022 - 11:43
Funding Opportunity RFA-DK-22-023 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified over 250 susceptibility loci for IBD. The IBDGC has recently been renewed with a continued mission to characterize the genetic architecture of IBD phenotypes in diverse populations and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology and clinical course. However, current resources permit functional investigation of only a limited number of loci, genes and physiological domains, while the biological mechanisms underlying most of the identified IBD risk loci remain unknown. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of IBD susceptibility loci, causal variants and effector genes, and IBD-related phenotypes and physiological domains under investigation via Ancillary Studies utilizing the extensive resources including subjects, samples and datasets established by the IBDGC. Proposed Ancillary Studies should focus on causal variant identification and/or functional characterization of effector genes within IBD risk loci and must not duplicate studies either ongoing or already completed by the IBDGC.

Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)

Fri, 12/23/2022 - 11:11
Funding Opportunity PAR-23-075 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.

Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)

Fri, 12/23/2022 - 10:18
Funding Opportunity PAR-23-083 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)

Fri, 12/23/2022 - 10:11
Funding Opportunity PAR-23-081 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

Pages